Y Intercept Hong Kong Ltd Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Y Intercept Hong Kong Ltd grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,297 shares of the company’s stock after purchasing an additional 1,995 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.10% of Syndax Pharmaceuticals worth $1,101,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $26,000. Quantbot Technologies LP purchased a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at $49,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after acquiring an additional 541 shares during the last quarter. KBC Group NV raised its holdings in shares of Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Syndax Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,367 shares of the company’s stock worth $315,000 after acquiring an additional 6,383 shares during the period.

Syndax Pharmaceuticals Stock Up 2.2 %

NASDAQ:SNDX opened at $15.57 on Thursday. Syndax Pharmaceuticals, Inc. has a 52 week low of $12.06 and a 52 week high of $25.34. The stock’s fifty day moving average is $14.04 and its two-hundred day moving average is $16.87. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.29 and a beta of 0.90.

Insider Activity at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares of the company’s stock, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SNDX. Scotiabank cut their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. increased their price target on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. Citigroup increased their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).